Research Information System
Acta Endocrinologica, vol.8, no.2, pp.321-329, 2012 (SCI-Expanded, Scopus)
Context. Bone mineral density (BMD) loss and progressive bone loss have been detected in patients with untreated hyperprolactinemia. It is unclear in patients with mild hyperprolactinemia.
Objective. The aim of the study was to evaluate bone metabolism through bone mineral density by using dual energy X-ray absorptiometry (DXA) and bone turnover markers in premenopausal women with prolactinoma
Design, Subjects and Methods. Twenty five patients newly diagnosed with prolactinoma and treated surgically and/or medically, hut whose prolactin levels were above the normal limits (PRL > 25 mu g/L) and 25 healthy controls were included in the study, which was conducted at the Cerrahpasa Medical School, Division of Endocrinology and Metabolism outpatient clinic. Bone mineral density was measured using the DXA method. Bone turn-over markers such as alkaline phosphatase (ALP), osteocalcin, Type I collagen N-telopeptide (NTX) and Type I collagen C-Telopeptide (CTX) levels were determined.
Results. The only significant difference in bone density (p=0.02) was in L4 lumbar vertebrae. There were no significant differences between the patient and the control groups in ALP, osteocalcin, NTX, and CTX levels.
Conclusion. There were no significant differences between the patient and the control groups in bone mineral density and bone turnover markers, except in the L4 lumbar vertebrae.